Generic drug-maker Actavis believes it will earn profits of around $100 million in the next two years from licensing patents owned by Purdue Pharma LP.
You need to login to continue reading this content.
News stories up to a week old on LSIPR are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email firstname.lastname@example.org.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
actavis, oxycontin, purdue pharma, Fitzpatrick, Cella, Harper & Scinto